Table 1.
Main features of the studies eligible for inclusion with median follow-up time > 5 years.
|
Author, Year |
Sample size (Recruitment period) |
Tumor Histology (WHO type) |
Stage (M−K) |
Margin status |
RT intent (n) |
RT technique (n) |
Median RT Dose in Gy (range) |
Median Follow-up months (range) |
|---|---|---|---|---|---|---|---|---|
| RECURRENCES of TETs | ||||||||
| Yang 2019 [39] | 47 (2007–2015) |
TETs (A-B3 + C) |
Recurr. | n/a | dRT (47) |
3D-CRT (29) IMRT (18) |
52 Gy (30–70) |
83 (8–299) |
| THYMOMA (M−K II) | ||||||||
| Chen 2010 [36] |
107* (1964–2006) |
Thymoma (A-B3) |
II | R0 | PORT (66) |
2D-RT (44) 3D-CRT (22) |
60 Gy (22–60) |
63 (2–303) |
Abbreviations: TETs = thymic epithelial tumors; WHO = World health organization; M−K = Masaoka-Koga surgical tumor stage classification; n/a = not applicable; PORT = Post operative RT; dRT = Radiotherapy alone with definitive or curative intent; 3D-CRT = 3D conformal radiotherapy; IMRT: Intensity modulated radiotherapy; R0 = complete resection; Recurr. = recurrence; n = number of patients.
*The original study sample differs from the patients undergoing RT with modern techniques (e.g. the final sample size used for the synthesis).